7b9625284b
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
22 lines
No EOL
996 B
Markdown
22 lines
No EOL
996 B
Markdown
# Semaglutide + CBT for Cocaine Use Disorder (Phase 2)
|
|
|
|
**Type:** Clinical trial
|
|
**Phase:** 2
|
|
**Status:** Recruiting (as of May 2026)
|
|
**Intervention:** Semaglutide combined with cognitive behavioral therapy (CBT)
|
|
**Population:** Adults with diagnosed cocaine use disorder and BMI ≥25
|
|
**Primary objective:** Reduce cocaine cravings and use
|
|
**Registry:** withpower.com/trial/phase-2-cocaine-related-disorders-10-2025
|
|
|
|
## Timeline
|
|
|
|
- **2025-10** — Trial opened for recruitment
|
|
- **2026-05** — Actively recruiting participants
|
|
|
|
## Context
|
|
|
|
This trial follows the All of Us observational finding (Abegaz et al., March 2026) showing 75% lower odds of cocaine use disorder in GLP-1 users (OR=0.25). Cocaine use disorder has no FDA-approved pharmacotherapy, making this a high-priority unmet need. The trial combines semaglutide with CBT, reflecting the behavioral-biological integration model seen in other GLP-1 SUD trials.
|
|
|
|
## Expected Results
|
|
|
|
Phase 2 results anticipated 2027-2028. |